Default company panoramic image

Emphymab Biotech

Emphymab Biotech is developing a first disease-modifying drug for emphysema and other chronic diseases

  • Stage Product In Development
  • Industry Biotechnology
  • Location Indianapolis, IN, USA
  • Currency USD
  • Founded May 2011
  • Employees 4

Company Summary

Emphymab is developing the first disease-modifying therapy that halts emphysema progression. Emphymab has developed a therapeutic antibody that neutralizes a inflammatory cytokine EMAPII that is enhanced in patients blocking lung destruction. After establishing proof-of-concept in clinical trials Emphymab will partner with a biopharma company. Emphymab has received a second Phases I SBIR and foundational support from the Harrington Institute.


  • Default avatar
    Joe Trebley, PhD
    Director of Business Operations

    Dr. Trebley’s background in early stage company management and therapeutic development provide the needed expertise to move EmphyMAb assets toward the clinic. Dr. Trebley has a track record for shepherding early-stage companies out of the university setting and into the private sector by obtaining early-stage management and financing, all of which will be of particular importance for EmphyMAb.

  • Default avatar
    Brian Johnstone, PhD
    Director of Preclinical Development

    Dr. Johnstone directs the early stage development of EmphyMAb’s lead therapeutic for COPD. Dr. Johnstone has over 15 years of experience in early stage biotech companies, where he has served in the executive leadership team, while directing preclinical development of biologics, DNA-based therapies and small molecules. His previous involvement with two early drug development programs has led to Phase I clinical trials.

  • Default avatar
    Irina Petrache, MD
    Medical Advisor

    Dr. Petrache is the lead medical advisor and a contributor to the research direction and clinical insights at EmphyMAb. Dr. Petrache is a physician scientist, board certified in Pulmonary and Critical Care Medicine, and principal investigator of a laboratory that studies mechanisms of lung injury and repair pertinent to cigarette smoke-induced chronic lung disease at Indiana University.

  • Default avatar
    Matthias Clauss, PhD
    Scientific Advisor

    Dr. Clauss maintains a multi-year research program examining the involvement of EMAPII in promoting endothelial cell death. This expertise will be invaluable for guiding the development of this antibody towards clinical application. His research program also involves the study of general mechanisms of endothelial cell death and senescence, with an overall aim of identifying the links between inflammation and angiogenesis.